A PYMNTS Company

Indivior Must Face Opioid Antitrust Suit

By  |  August 23, 2022

Drugmaker Indivior must face a lawsuit by 42 state attorneys general accusing it of using illegal tactics to shield its opioid addiction treatment Suboxone from generic competition, a federal judge has ruled.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    US District Judge Mitchell Goldberg in Philadelphia found Monday that a reasonable jury could find that Indivior’s switch from a pill to an oral film form of the drug in 2009 was intended to extend its monopoly just as generic manufacturers were poised to begin selling their own pills, a strategy known as product hopping. He denied the Virginia-based company’s motion for a judgment in its favor.

    States have said that the company’s conduct forced consumers to pay inflated prices for the treatment amid an epidemic of opioid addiction.

    “The cost of critical medication must not be inflated through anticompetitive tactics,” Wisconsin Attorney General Josh Kaul, who is leading the multistate coalition, said in a statement.

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.